Pacific Biosciences Of California Stock News

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

During the last session, Pacific Biosciences of California Inc. (NASDAQ:PACB)’s traded shares were 2.28 million, with the beta value of the company hitting 1.33. At the end of the trading day, the stock’s price was $10.94, reflecting an intraday loss of -2.58% or -$0.29. The 52-week high for the PACB share is $37.42, that puts … Does Pacific Biosciences of California Inc. (NASDAQ: PACB) Still Look Attractive After A -3.19% Selloff Last Week? Read More »

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

WASHINGTON, March 07, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Genomics in Cancer Care Market finds that rising demand for technologically advanced & cost-efficient diagnostic technology and increasing demand for diagnostics centres are augmenting the growth of Genomics in Cancer Care Market in upcoming years. In addition, growing research activities for the development of novel treatment therapies and increasing funding for the development of pharmaceutical and biotech industry are some other important parameters that bolstering the market demand in the projected time span. The total Global Genomics in Cancer Care Market is estimated to reach USD 40.5 Billion by 2028. The market stood at a revenue of USD 12.1 Billion in the year 2021, and expected to grow at a Compound Annual Growth Rate (CAGR) of 16.1%, states Vantage Market Research, in a report, titled " Genomics in Cancer Care Market by Product (Instruments, Consumables, Services), by Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), by Technology (Genome Sequencing, PCR, Microarrays, Nucleic Acid Extraction & Purification), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee

Pacific Biosciences of California Inc. (NASDAQ:PACB) has a beta value of 1.35 and has seen 8.43 million shares traded in the last trading session. The company, currently valued at $2.43B, closed the last trade at $11.47 per share which meant it gained $0.44 on the day or 3.99% during that session. The PACB stock price Pacific Biosciences of California Inc. (PACB) Suffers From Weak Fundamental Momentum Read More »

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences (PACB) has lost ~10% in the pre-market on Wednesday after several Wall Street analysts slashed their price targets on the life sciences company in reaction to…

PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on

Futures Tread Water Ahead Of FOMC Mintues As Russia Forgets To Invade Ukraine The global rally stalled on Wednesday, and U.S. index futures were flat, treading water after a quiet overnight session, ahead of today''s FOMC minutes which some hope will unveil more detail on the Fed''s upcoming rate hike and QT, while also weighing the risks from the Ukraine tensions against inflation and tighter monetary policy. S&P 500 futures were flat and Nasdaq futures were little changed by 7:15 a.m. in New York, trimming earlier gains after NATO Sec. Stoltenberg pushed back on claims of Russian troop withdrawals, adding he is yet to see signs of a de-escalation. Treasury yields, bitcoin, gold and the dollar were also all flat. Oil recovered after the biggest one-day loss this year as worries about potential disruptions to commodity supplies eased. Making a mockery of the Deep State/CIA/CNN which predicted that a Russian invasion would take place today, the Russian defense ministry announced more troops were returning to their bases after maneuvers ended in Crimea, while western officials remained cautious.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.